

## The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

Simon Rule,<sup>1</sup> Paul Smith,<sup>2</sup> Peter W.M. Johnson,<sup>3</sup> Simon Bolam,<sup>4</sup> George Follows,<sup>5</sup> Joanne Gambell,<sup>2</sup> Peter Hillmen,<sup>6</sup> Andrew Jack,<sup>7</sup> Stephen Johnson,<sup>4</sup> Amy A Kirkwood,<sup>2</sup> Anton Kruger,<sup>8</sup> Christopher Pocock,<sup>9</sup> John F. Seymour,<sup>10</sup> Milena Toncheva,<sup>2</sup> Jan Walewski<sup>11</sup> and David Linch<sup>12</sup>

<sup>1</sup>Derriford Hospital, Plymouth, UK; <sup>2</sup>Cancer Research UK and UCL Cancer Trials Centre, London, UK; <sup>3</sup>University of Southampton, Southampton, UK; <sup>4</sup>Musgrove Park Hospital, Taunton, UK; <sup>5</sup>Addenbrookes Hospital, Cambridge, UK; <sup>6</sup>St. James's University Hospital, Leeds, UK; <sup>7</sup>HMDs, Leeds General Infirmary, UK; <sup>8</sup>Royal Cornwall Hospital, Truro, UK; <sup>9</sup>Kent and Canterbury Hospital, Canterbury, UK; <sup>10</sup>The Peter MacCallum Cancer Centre, Melbourne, Australia; <sup>11</sup>Maria Skłodowska-Curie Institute and Oncology Centre, Gilwice, Poland; and <sup>12</sup>UCL Cancer Institute, London, UK

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.128710

Received: 9/4/2015.


Accepted: 19/11/2015.

Pre-published: 26/11/2015.

Correspondence: engx2@nhlbi.nih.gov

---

Supplement figure 1. Consort diagram



<sup>1</sup>At least one complete cycle

<sup>2</sup>Two patients received FC cycles 2-8, one FC on cycles 2-6 and one 2-4

<sup>3</sup>All patients were included in the main intention to treat analysis.

A complete cycle was classified as a cycle which included at least one dose of each drug.